Differentiating Hypoglycemia from other diseases: Difference between revisions
Ahmed Younes (talk | contribs) No edit summary |
|||
(19 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Hypoglycemia]] | |||
{{CMG}}; {{AE}} {{MAD}} | {{CMG}}; {{AE}} {{MAD}} | ||
==Overview== | ==Overview== | ||
Hypoglycemia should be differentiated from other causes of autonomic | Hypoglycemia should be differentiated from other causes of [[autonomic]] hyperactivity symptoms. Neonatal hypoglycemia should be differentiated from other causes of neurological symptoms in neonates such as [[sepsis]], metabolic diseases: [[urea cycle disorders]], and branched-chain organic acidemias, [[hyponatremia]] and [[Asphyxia|neonatal asphyxia]]. In adults, hypoglycemia should be differentiated from other diseases that may cause autonomic hyperactivity symptoms, such as [[hyperthyroidism]], [[anxiety]], [[Cardiac arrhythmia|arrhythmia]], and [[pheochromocytoma]]. | ||
==Differentiating Hypoglycemia from other Diseases== | ==Differentiating Hypoglycemia from other Diseases== | ||
==== Differentiating Different Causes of Hypoglycemia from each other: ==== | |||
==== Hypoglycemia | |||
{| class="wikitable" | {| class="wikitable" | ||
! | ! | ||
! | !Fasting symptoms | ||
!Postprandial symptoms | !Postprandial symptoms | ||
!Plasma insulin | !Plasma [[insulin]] | ||
!C-peptide | ![[C-peptide]] | ||
!proinsulin | ![[proinsulin]] | ||
!Sulfonylurea in plasma | ![[Sulfonylurea]] in plasma | ||
!insulin or insulin receptor antibodies | !insulin or insulin receptor antibodies | ||
|- | |- | ||
|Insulinoma | |[[Insulinoma]] | ||
| + | | + | ||
| - | | - | ||
Line 91: | Line 36: | ||
| - | | - | ||
|- | |- | ||
|Autoimmune hypoglycemia | |Autoimmune hypoglycemia | ||
| - | | - | ||
| - | | - | ||
Line 109: | Line 54: | ||
| - | | - | ||
|- | |- | ||
|Exogenous insulin | |Exogenous [[insulin]] | ||
| - | | - | ||
| - | | - | ||
Line 129: | Line 74: | ||
<nowiki>*</nowiki>(NIPHS) non-insulinoma pancreatogenous hypoglycemia syndrome | <nowiki>*</nowiki>(NIPHS) non-insulinoma pancreatogenous hypoglycemia syndrome | ||
==== | *'''Differentials for [[Hypoglycemia]] on the basis of Laboratory findings:'''<ref name="pmid19088155">{{cite journal| author=Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER et al.| title=Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 3 | pages= 709-28 | pmid=19088155 | doi=10.1210/jc.2008-1410 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19088155 }} </ref> | ||
{| class="sortable" | |||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |||
! rowspan="2" |Diagnoses | |||
! colspan="8" |Laboratory Findings differentiating among causes of Hypoglycemia | |||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |||
!S.Glucose<br>(mg/dL) | |||
!C Peptide (pmol/L) | |||
!S.Insulin (μU/mL) | |||
!S.Proinsulin<br>(pmol/L) | |||
!S. Beta hydroxybutyrate | |||
!Glucose increase after glucagon(mg/dL) | |||
!Oral Hypoglycemic agent | |||
!Antibodies to Insulin | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Normal/Fasting | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<200 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<3 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<5 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>2.7 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<25 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Exogenous Insulin | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<200 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>>3 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<5 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |≤2.7 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>25 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Insulinoma]] | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" |≥200 | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" |≥3 | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" |≥5 | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" |≤2.7 | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" |>25 | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
| rowspan="3" style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nesidioblastosis]] | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post gastric bypass hypoglycemia (PGPH) | |||
|- | |||
| style="background: #DCDCDC; padding: 5px;text-align: center;" |Insulin autoimmune hypoglycemia | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>>200<sup>‡</sup> | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>>3 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>>5<sup>‡</sup> | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |≤2.7 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>25 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | + | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Oral hypoglycemic agent]] | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |≥200 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |S. | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |≥5 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |≤2.7 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>25 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | + | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[IGF]]¤ | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<55 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<200 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<3 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |<5 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |≤2.7 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" |>25 | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
| style="background: #F5F5F5; padding: 5px;text-align: center;" | - | |||
|- | |||
| colspan="9" style="background: #DCDCDC; padding: 5px; " | | |||
‡ Free C-peptide and proinsulin concentrations are low<br> | |||
¤ [[IGF]]= Insulin Growth Factor, Increased pro-IGF-2, free [[Insulin-like growth factor 2|IGF]]-2, IGF-2/[[IGF-1]] ratio | |||
|} | |||
==== Differentiating Hypoglycemia from other diseases that cause autonomic hyperactivity symptoms: ==== | |||
{| class="wikitable" | |||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; " |Disease | |||
! colspan="5" style="background: #4479BA; color: #FFFFFF; " |Clinical Manifestation | |||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; " |Investigations | |||
|- | |||
! colspan="4" style="background: #4479BA; color: #FFFFFF; " |Symptoms | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; " |Signs | |||
|- | |||
! style="background: #4479BA; color: #FFFFFF; " |Palpitations | |||
! style="background: #4479BA; color: #FFFFFF; " |Fever | |||
! style="background: #4479BA; color: #FFFFFF; " |Sweating | |||
! style="background: #4479BA; color: #FFFFFF; " |Headache | |||
|- | |||
![[Hypoglycemia]] | |||
| + | |||
| - | |||
| + | |||
| + | |||
| | |||
* [[Tachycardia]] | |||
* Blurred vision | |||
* [[Pallor]] | |||
* [[Tremor|Tremors]] | |||
* [[Seizures]]/ [[Coma]] | |||
| | |||
* Plasma [[glucose]] <70 mg/dL | |||
* Serum [[Insulin]] level | |||
* Serum [[Proinsulin]] | |||
* Serum [[C-peptide|C-Peptide]] | |||
|- | |||
![[Anxiety disorders]] | |||
|<nowiki>+</nowiki> | |||
|<nowiki>-</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | |||
* Patient looks [[irritable]] | |||
* Rapid [[pulse]] and may be irregular | |||
| | |||
* Psychiatry evaluation | |||
|- | |||
![[Pheochromocytoma]]<ref name="pmid11903030">{{cite journal| author=Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P et al.| title=Biochemical diagnosis of pheochromocytoma: which test is best? | journal=JAMA | year= 2002 | volume= 287 | issue= 11 | pages= 1427-34 | pmid=11903030 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11903030 }}</ref><ref name="pmid1787652">{{cite journal| author=Bravo EL| title=Pheochromocytoma: new concepts and future trends. | journal=Kidney Int | year= 1991 | volume= 40 | issue= 3 | pages= 544-56 | pmid=1787652 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1787652 }}</ref> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | |||
* [[Tachycardia]] | |||
* Strong rapid [[pulse]] | |||
* High [[pulse pressure]] | |||
| | |||
* Plasma fractionated [[Metanephrine|metanephrines]], 24-hour urinary fractionated [[Metanephrine|metanephrines]], [[catecholamines]]. | |||
* [[Computed tomography]]: Radiological evaluation should follow lab tests to locate site of the [[tumor]]<nowiki/>r. | |||
|- | |||
![[Arrhythmias|Arrhythmia]] | |||
| + | |||
|<nowiki>-</nowiki> | |||
|<nowiki>-</nowiki> | |||
|<nowiki>-</nowiki> | |||
| | |||
* Irregular pulse | |||
| | |||
* ECG changes according to the cause | |||
|- | |||
![[Hyperthyroidism]] | |||
| + | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | |||
* Hyperactive [[Deep tendon reflex|deep tendon reflexes]] | |||
* [[Thyromegaly]] | |||
* [[Exophthalmus]] | |||
| | |||
* Level of [[thyroid-stimulating hormone]] ([[TSH]]) | |||
* Levels of T4 and/or T3 in the blood | |||
* [[Antibody|Antibodies]] such as anti-[[TSH receptor|TSH-receptor antibodies]] in [[Graves' disease]] | |||
|} | |||
==== Differentiating Hypoglycemia from other Diseases that Cause Neurological Symptoms in Neonates: ==== | |||
{| class="wikitable" | {| class="wikitable" | ||
! rowspan="2" |Disease | ! rowspan="2" |Disease | ||
Line 139: | Line 252: | ||
!Improvement of symptoms with glucose intake | !Improvement of symptoms with glucose intake | ||
!Fever | !Fever | ||
!Hepatomegaly | ![[Hepatomegaly]] | ||
|- | |- | ||
|[[Hypoglycemia]] | |||
| + | |||
| + | |||
| + | |||
| - | |||
| - | |||
| | |||
* Blood glucose level | |||
|- | |- | ||
|Sepsis | |[[Sepsis]] | ||
| - | | - | ||
|<nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | | <nowiki>-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | | <nowiki>-</nowiki> | ||
|Blood cultures | | | ||
* Blood cultures | |||
|- | |- | ||
|Inborn errors of metabolism | |[[Inborn error of metabolism|Inborn errors of metabolism]] | ||
| | | <nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | | <nowiki>-</nowiki> | ||
| - | | - | ||
|<nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
|Positive blood tests | | | ||
* Positive blood tests | |||
|- | |- | ||
|Hyponatremia | |[[Hyponatremia]] | ||
| - | | - | ||
|<nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | | <nowiki>-</nowiki> | ||
| - | | - | ||
|<nowiki>-</nowiki> | | <nowiki>-</nowiki> | ||
|Plasma sodium falls below 125 mEq/L | | | ||
* Plasma sodium falls below 125 mEq/L | |||
|- | |- | ||
|Perinatal asphyxia | |[[Perinatal asphyxia]] | ||
|<nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | | <nowiki>+</nowiki> | ||
| - | | - | ||
| - | | - | ||
|<nowiki>-</nowiki> | | <nowiki>-</nowiki> | ||
|MRI of acute brain injury confirms the diagnosis of encephalopathy | | | ||
* MRI of acute brain injury confirms the diagnosis of encephalopathy | |||
|} | |} | ||
===Differentiating | ====Differentiating Hypoglycemia from other Diseases that Cause Coma and Consciousness Alterations: ==== | ||
{| | {| | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="2" |<small>Diseases</small> | ! rowspan="2" |<small>Diseases</small> | ||
! colspan=" | ! colspan="3" |<small>Diagnostic tests</small> | ||
! colspan="5" |<small>Physical Examination</small> | ! colspan="5" |<small>Physical Examination</small> | ||
! colspan="3" |<small>Symptoms | ! colspan="3" |<small>Symptoms | ||
Line 192: | Line 310: | ||
! rowspan="2" |<small>Other Findings</small> | ! rowspan="2" |<small>Other Findings</small> | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!<small>CT /MRI</small> | !<small>CT /MRI</small> | ||
!<small>CSF Findings</small> | !<small>CSF Findings</small> | ||
Line 204: | Line 321: | ||
!<small>Fever</small> | !<small>Fever</small> | ||
!<small>Altered mental status</small> | !<small>Altered mental status</small> | ||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hypoglycemia]] | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" |Serum blood [[Glucose-1-phosphate adenylyltransferase|glucose]] | |||
[[HbA1c]] | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" |✔ | |||
| style="background: #F5F5F5; padding: 5px;text-align:center" | | |||
| style="background: #F5F5F5; padding: 5px;text-align:center" | | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px; text-align:center" | ✔ | |||
| style="background: #F5F5F5; padding: 5px; text-align:center" | | |||
| style="background: #F5F5F5; padding: 5px;" |✔ | |||
| style="background: #F5F5F5; padding: 5px;" |History of [[Diabetes mellitus|diabetes]] | |||
| style="background: #F5F5F5; padding: 5px;" |[[Palpitation|Palpitations]], [[sweating]], [[dizziness]], low serum, [[glucose]] | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Brain tumour|Brain tumor]]<ref name="pmid1278192">Soffer D (1976) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1278192 Brain tumors simulating purulent meningitis.] ''Eur Neurol'' 14 (3):192-7. PMID: [http://pubmed.gov/1278192 1278192]</ref><ref name="pmid3883130" /> | | style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Brain tumour|Brain tumor]]<ref name="pmid1278192">Soffer D (1976) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1278192 Brain tumors simulating purulent meningitis.] ''Eur Neurol'' 14 (3):192-7. PMID: [http://pubmed.gov/1278192 1278192]</ref><ref name="pmid3883130" /> | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px text-align:center" |Cancer cells<ref name="pmid21371327">{{cite journal| author=Weston CL, Glantz MJ, Connor JR| title=Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. | journal=Fluids Barriers CNS | year= 2011 | volume= 8 | issue= 1 | pages= 14 | pmid=21371327 | doi=10.1186/2045-8118-8-14 | pmc=3059292 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21371327 }}</ref> | | style="background: #F5F5F5; padding: 5px text-align:center" |[[Cancer]] cells<ref name="pmid21371327">{{cite journal| author=Weston CL, Glantz MJ, Connor JR| title=Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. | journal=Fluids Barriers CNS | year= 2011 | volume= 8 | issue= 1 | pages= 14 | pmid=21371327 | doi=10.1186/2045-8118-8-14 | pmc=3059292 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21371327 }}</ref> | ||
| style="background: #F5F5F5; padding: 5px;" |MRI | | style="background: #F5F5F5; padding: 5px;" |MRI | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" | | | style="background: #F5F5F5; padding: 5px; text-align:center" | | ||
Line 222: | Line 354: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Delirium tremens]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Delirium tremens]] | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 234: | Line 365: | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |[[Alcohol]] intake, sudden | | style="background: #F5F5F5; padding: 5px;" |[[Alcohol]] intake, sudden withdrawal or reduction in consumption | ||
| style="background: #F5F5F5; padding: 5px;" |[[Tachycardia]], [[diaphoresis]], [[hypertension]], [[tremors]], [[mydriasis]], [[positional nystagmus]], | | style="background: #F5F5F5; padding: 5px;" |[[Tachycardia]], [[diaphoresis]], [[hypertension]], [[tremors]], [[mydriasis]], [[positional nystagmus]], | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Subarachnoid hemorrhage|Subarachnoid hemorrhage]]<ref name="pmid14585453">Yeh ST, Lee WJ, Lin HJ, Chen CY, Te AL, Lin HJ (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=14585453 Nonaneurysmal subarachnoid hemorrhage secondary to tuberculous meningitis: report of two cases.] ''J Emerg Med'' 25 (3):265-70. PMID: [http://pubmed.gov/14585453 14585453]</ref> | | style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Subarachnoid hemorrhage|Subarachnoid hemorrhage]]<ref name="pmid14585453">Yeh ST, Lee WJ, Lin HJ, Chen CY, Te AL, Lin HJ (2003) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=14585453 Nonaneurysmal subarachnoid hemorrhage secondary to tuberculous meningitis: report of two cases.] ''J Emerg Med'' 25 (3):265-70. PMID: [http://pubmed.gov/14585453 14585453]</ref> | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |Xanthochromia<ref name="pmid1198628">{{cite journal| author=Lee MC, Heaney LM, Jacobson RL, Klassen AC| title=Cerebrospinal fluid in cerebral hemorrhage and infarction. | journal=Stroke | year= 1975 | volume= 6 | issue= 6 | pages= 638-41 | pmid=1198628 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1198628 }}</ref> | | style="background: #F5F5F5; padding: 5px;" |[[Xanthochromic|Xanthochromia]]<ref name="pmid1198628">{{cite journal| author=Lee MC, Heaney LM, Jacobson RL, Klassen AC| title=Cerebrospinal fluid in cerebral hemorrhage and infarction. | journal=Stroke | year= 1975 | volume= 6 | issue= 6 | pages= 638-41 | pmid=1198628 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1198628 }}</ref> | ||
| style="background: #F5F5F5; padding: 5px;" |CT scan | | style="background: #F5F5F5; padding: 5px;" |CT scan without contrast<ref name="pmid21694755">{{cite journal| author=Birenbaum D, Bancroft LW, Felsberg GJ| title=Imaging in acute stroke. | journal=West J Emerg Med | year= 2011 | volume= 12 | issue= 1 | pages= 67-76 | pmid=21694755 | doi= | pmc=3088377 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21694755 }}</ref><ref name="pmid21807345">{{cite journal| author=DeLaPaz RL, Wippold FJ, Cornelius RS, Amin-Hanjani S, Angtuaco EJ, Broderick DF et al.| title=ACR Appropriateness Criteria® on cerebrovascular disease. | journal=J Am Coll Radiol | year= 2011 | volume= 8 | issue= 8 | pages= 532-8 | pmid=21807345 | doi=10.1016/j.jacr.2011.05.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21807345 }}</ref> | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
Line 255: | Line 384: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Stroke]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Stroke]] | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" | Normal | | style="background: #F5F5F5; padding: 5px; text-align:center" | Normal | ||
Line 271: | Line 399: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Neurosyphilis]]<ref name="pmid22482824">{{cite journal| author=Liu LL, Zheng WH, Tong ML, Liu GL, Zhang HL, Fu ZG et al.| title=Ischemic stroke as a primary symptom of neurosyphilis among HIV-negative emergency patients. | journal=J Neurol Sci | year= 2012 | volume= 317 | issue= 1-2 | pages= 35-9 | pmid=22482824 | doi=10.1016/j.jns.2012.03.003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22482824 }} </ref><ref name="pmid24365430">{{cite journal |vauthors=Berger JR, Dean D |title=Neurosyphilis |journal=Handb Clin Neurol |volume=121 |issue= |pages=1461–72 |year=2014 |pmid=24365430 |doi=10.1016/B978-0-7020-4088-7.00098-5 |url=}}</ref> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Neurosyphilis]]<ref name="pmid22482824">{{cite journal| author=Liu LL, Zheng WH, Tong ML, Liu GL, Zhang HL, Fu ZG et al.| title=Ischemic stroke as a primary symptom of neurosyphilis among HIV-negative emergency patients. | journal=J Neurol Sci | year= 2012 | volume= 317 | issue= 1-2 | pages= 35-9 | pmid=22482824 | doi=10.1016/j.jns.2012.03.003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22482824 }} </ref><ref name="pmid24365430">{{cite journal |vauthors=Berger JR, Dean D |title=Neurosyphilis |journal=Handb Clin Neurol |volume=121 |issue= |pages=1461–72 |year=2014 |pmid=24365430 |doi=10.1016/B978-0-7020-4088-7.00098-5 |url=}}</ref> | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |'''↑''' [[Leukocytes]] and [[protein]] | | style="background: #F5F5F5; padding: 5px;" |'''↑''' [[Leukocytes]] and [[protein]] | ||
Line 290: | Line 417: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Viral encephalitis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Viral encephalitis]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |Increased [[RBC]]S or xanthochromia, [[Mononuclear cells|mononuclear]] [[lymphocytosis]], high protein content, normal [[glucose]] | | style="background: #F5F5F5; padding: 5px;" |Increased [[RBC]]S or xanthochromia, [[Mononuclear cells|mononuclear]] [[lymphocytosis]], high protein content, normal [[glucose]] | ||
Line 306: | Line 432: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Herpes simplex encephalitis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Herpes simplex encephalitis]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 321: | Line 446: | ||
| style="background: #F5F5F5; padding: 5px;" |[[Delirium]], cortical [[blindness]], [[cerebral edema]], [[seizure]] | | style="background: #F5F5F5; padding: 5px;" |[[Delirium]], cortical [[blindness]], [[cerebral edema]], [[seizure]] | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Wernicke’s encephalopathy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Wernicke's encephalopathy|Wernicke’s encephalopathy]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Normal | | style="background: #F5F5F5; padding: 5px;" |Normal | ||
Line 338: | Line 462: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[CNS abscess]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[CNS abscess]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |'''↑''' [[leukocytes]] >100,000/ul, '''↓''' [[glucose]] | | style="background: #F5F5F5; padding: 5px;" |'''↑''' [[leukocytes]] >100,000/ul, '''↓''' [[glucose]], '''↑'''[[protein]], '''↑''' red blood cells, and [[lactic acid]] >500mg | ||
| style="background: #F5F5F5; padding: 5px;" |Contrast enhanced MRI is more sensitive and specific, | | style="background: #F5F5F5; padding: 5px;" |Contrast enhanced MRI is more sensitive and specific, | ||
[[Histopathological]] examination of brain tissue | [[Histopathological]] examination of [[brain]] tissue | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
Line 352: | Line 475: | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |History of [[drug abuse]], [[endocarditis]], '''↓''' [[immune]] status | | style="background: #F5F5F5; padding: 5px;" |History of [[drug abuse]], [[endocarditis]], '''↓''' [[immune]] status | ||
| style="background: #F5F5F5; padding: 5px;" |High grade [[fever]], [[fatigue]], [[Nausea and vomiting|nausea]], [[vomiting]] | | style="background: #F5F5F5; padding: 5px;" |High-grade [[fever]], [[fatigue]], [[Nausea and vomiting|nausea]], [[vomiting]] | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Drug toxicity]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Drug toxicity]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 371: | Line 493: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Conversion disorder]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Conversion disorder]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 387: | Line 508: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Electrolyte disturbance]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Electrolyte disturbance]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 403: | Line 523: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Febrile convulsion]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Febrile convulsion]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |Not performed in first simple febrile [[seizures]] | | style="background: #F5F5F5; padding: 5px; text-align:center" |Not performed in first simple febrile [[seizures]] | ||
Line 419: | Line 538: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Subdural empyema]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Subdural empyema]] | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | | style="background: #F5F5F5; padding: 5px; text-align:center" |✔ | ||
| style="background: #F5F5F5; padding: 5px; text-align:center" | | | style="background: #F5F5F5; padding: 5px; text-align:center" | | ||
Line 433: | Line 551: | ||
| style="background: #F5F5F5; padding: 5px;" |History of relapses and remissions | | style="background: #F5F5F5; padding: 5px;" |History of relapses and remissions | ||
| style="background: #F5F5F5; padding: 5px;" |Blurry vision, [[urinary incontinence]], [[fatigue]] | | style="background: #F5F5F5; padding: 5px;" |Blurry vision, [[urinary incontinence]], [[fatigue]] | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Latest revision as of 22:39, 25 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Hypoglycemia should be differentiated from other causes of autonomic hyperactivity symptoms. Neonatal hypoglycemia should be differentiated from other causes of neurological symptoms in neonates such as sepsis, metabolic diseases: urea cycle disorders, and branched-chain organic acidemias, hyponatremia and neonatal asphyxia. In adults, hypoglycemia should be differentiated from other diseases that may cause autonomic hyperactivity symptoms, such as hyperthyroidism, anxiety, arrhythmia, and pheochromocytoma.
Differentiating Hypoglycemia from other Diseases
Differentiating Different Causes of Hypoglycemia from each other:
Fasting symptoms | Postprandial symptoms | Plasma insulin | C-peptide | proinsulin | Sulfonylurea in plasma | insulin or insulin receptor antibodies | |
---|---|---|---|---|---|---|---|
Insulinoma | + | - | high | high | high | - | - |
Oral hypoglycemia agent-induced | - | - | high | high | high | + | - |
Autoimmune hypoglycemia | - | - | high | high | high | - | + |
NIPHS* | - | + | high | high | high | - | - |
Exogenous insulin | - | - | high | low | low | - | - |
Non-islet cell tumors | - | - | low | low | low | - | - |
*(NIPHS) non-insulinoma pancreatogenous hypoglycemia syndrome
- Differentials for Hypoglycemia on the basis of Laboratory findings:[1]
Diagnoses | Laboratory Findings differentiating among causes of Hypoglycemia | |||||||
---|---|---|---|---|---|---|---|---|
S.Glucose (mg/dL) |
C Peptide (pmol/L) | S.Insulin (μU/mL) | S.Proinsulin (pmol/L) |
S. Beta hydroxybutyrate | Glucose increase after glucagon(mg/dL) | Oral Hypoglycemic agent | Antibodies to Insulin | |
Normal/Fasting | <55 | <200 | <3 | <5 | >2.7 | <25 | - | - |
Exogenous Insulin | <55 | <200 | >>3 | <5 | ≤2.7 | >25 | - | - |
Insulinoma | <55 | ≥200 | ≥3 | ≥5 | ≤2.7 | >25 | - | - |
Nesidioblastosis | ||||||||
Post gastric bypass hypoglycemia (PGPH) | ||||||||
Insulin autoimmune hypoglycemia | <55 | >>200‡ | >>3 | >>5‡ | ≤2.7 | >25 | - | + |
Oral hypoglycemic agent | <55 | ≥200 | S. | ≥5 | ≤2.7 | >25 | + | - |
IGF¤ | <55 | <200 | <3 | <5 | ≤2.7 | >25 | - | - |
‡ Free C-peptide and proinsulin concentrations are low |
Differentiating Hypoglycemia from other diseases that cause autonomic hyperactivity symptoms:
Disease | Clinical Manifestation | Investigations | ||||
---|---|---|---|---|---|---|
Symptoms | Signs | |||||
Palpitations | Fever | Sweating | Headache | |||
Hypoglycemia | + | - | + | + |
|
|
Anxiety disorders | + | - | + | + |
|
|
Pheochromocytoma[2][3] | + | + | + | + |
|
|
Arrhythmia | + | - | - | - |
|
|
Hyperthyroidism | + | + | + | + |
|
|
Differentiating Hypoglycemia from other Diseases that Cause Neurological Symptoms in Neonates:
Disease | History and symptoms | Investigations | ||||
---|---|---|---|---|---|---|
Family History | Lethargy and irritability | Improvement of symptoms with glucose intake | Fever | Hepatomegaly | ||
Hypoglycemia | + | + | + | - | - |
|
Sepsis | - | + | - | + | - |
|
Inborn errors of metabolism | + | + | - | - | + |
|
Hyponatremia | - | + | - | - | - |
|
Perinatal asphyxia | + | + | - | - | - |
|
Differentiating Hypoglycemia from other Diseases that Cause Coma and Consciousness Alterations:
Diseases | Diagnostic tests | Physical Examination | Symptoms | Past medical history | Other Findings | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CT /MRI | CSF Findings | Gold standard test | Neck stiffness | Motor or Sensory deficit | Papilledema | Bulging fontanelle | Cranial nerves | Headache | Fever | Altered mental status | |||
Hypoglycemia | Serum blood glucose | ✔ | ✔ | ✔ | History of diabetes | Palpitations, sweating, dizziness, low serum, glucose | |||||||
Brain tumor[4][5] | ✔ | Cancer cells[6] | MRI | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | Cachexia, gradual progression of symptoms | |||
Delirium tremens | ✔ | Clinical diagnosis | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | Alcohol intake, sudden withdrawal or reduction in consumption | Tachycardia, diaphoresis, hypertension, tremors, mydriasis, positional nystagmus, | |||
Subarachnoid hemorrhage[7] | ✔ | Xanthochromia[8] | CT scan without contrast[9][10] | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | Trauma/fall | Confusion, dizziness, nausea, vomiting |
Stroke | ✔ | Normal | CT scan without contrast | ✔ | ✔ | ✔ | ✔ | ✔ | TIAs, hypertension, diabetes mellitus | Speech difficulty, gait abnormality | |||
Neurosyphilis[11][12] | ✔ | ↑ Leukocytes and protein | CSF VDRL-specific
CSF FTA-Ab -sensitive[13] |
✔ | ✔ | ✔ | ✔ | ✔ | ✔ | Unprotected sexual intercourse, STIs | Blindness, confusion, depression,
Abnormal gait | ||
Viral encephalitis | ✔ | Increased RBCS or xanthochromia, mononuclear lymphocytosis, high protein content, normal glucose | Clinical assesment | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | Tick bite/mosquito bite/ viral prodrome for several days | Extreme lethargy, rash hepatosplenomegaly, lymphadenopathy, behavioral changes | |
Herpes simplex encephalitis | ✔ | Clinical assesment | ✔ | ✔ | ✔ | ✔ | ✔ | History of hypertension | Delirium, cortical blindness, cerebral edema, seizure | ||||
Wernicke’s encephalopathy | Normal | ✔ | ✔ | ✔ | History of alcohol abuse | Ophthalmoplegia, confusion | |||||||
CNS abscess | ✔ | ↑ leukocytes >100,000/ul, ↓ glucose, ↑protein, ↑ red blood cells, and lactic acid >500mg | Contrast enhanced MRI is more sensitive and specific,
Histopathological examination of brain tissue |
✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | History of drug abuse, endocarditis, ↓ immune status | High-grade fever, fatigue, nausea, vomiting | |
Drug toxicity | ✔ | ✔ | Lithium, Sedatives, phenytoin, carbamazepine | ||||||||||
Conversion disorder | Diagnosis of exclusion | ✔ | ✔ | ✔ | ✔ | ✔ | Tremors, blindness, difficulty swallowing | ||||||
Electrolyte disturbance | Depends on the cause | ✔ | ✔ | Confusion, seizures | |||||||||
Febrile convulsion | Not performed in first simple febrile seizures | Clinical diagnosis and EEG | ✔ | ✔ | ✔ | ✔ | Family history of febrile seizures, viral illness or gastroenteritis | Age > 1 month, | |||||
Subdural empyema | ✔ | Clinical assessment and MRI | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | History of relapses and remissions | Blurry vision, urinary incontinence, fatigue |
References
- ↑ Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.
- ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.
- ↑ Bravo EL (1991). "Pheochromocytoma: new concepts and future trends". Kidney Int. 40 (3): 544–56. PMID 1787652.
- ↑ Soffer D (1976) Brain tumors simulating purulent meningitis. Eur Neurol 14 (3):192-7. PMID: 1278192
- ↑
- ↑ Weston CL, Glantz MJ, Connor JR (2011). "Detection of cancer cells in the cerebrospinal fluid: current methods and future directions". Fluids Barriers CNS. 8 (1): 14. doi:10.1186/2045-8118-8-14. PMC 3059292. PMID 21371327.
- ↑ Yeh ST, Lee WJ, Lin HJ, Chen CY, Te AL, Lin HJ (2003) Nonaneurysmal subarachnoid hemorrhage secondary to tuberculous meningitis: report of two cases. J Emerg Med 25 (3):265-70. PMID: 14585453
- ↑ Lee MC, Heaney LM, Jacobson RL, Klassen AC (1975). "Cerebrospinal fluid in cerebral hemorrhage and infarction". Stroke. 6 (6): 638–41. PMID 1198628.
- ↑ Birenbaum D, Bancroft LW, Felsberg GJ (2011). "Imaging in acute stroke". West J Emerg Med. 12 (1): 67–76. PMC 3088377. PMID 21694755.
- ↑ DeLaPaz RL, Wippold FJ, Cornelius RS, Amin-Hanjani S, Angtuaco EJ, Broderick DF; et al. (2011). "ACR Appropriateness Criteria® on cerebrovascular disease". J Am Coll Radiol. 8 (8): 532–8. doi:10.1016/j.jacr.2011.05.010. PMID 21807345.
- ↑ Liu LL, Zheng WH, Tong ML, Liu GL, Zhang HL, Fu ZG; et al. (2012). "Ischemic stroke as a primary symptom of neurosyphilis among HIV-negative emergency patients". J Neurol Sci. 317 (1–2): 35–9. doi:10.1016/j.jns.2012.03.003. PMID 22482824.
- ↑ Berger JR, Dean D (2014). "Neurosyphilis". Handb Clin Neurol. 121: 1461–72. doi:10.1016/B978-0-7020-4088-7.00098-5. PMID 24365430.
- ↑ Ho EL, Marra CM (2012). "Treponemal tests for neurosyphilis--less accurate than what we thought?". Sex Transm Dis. 39 (4): 298–9. doi:10.1097/OLQ.0b013e31824ee574. PMC 3746559. PMID 22421697.